Question · Panya answer

Is a sermorelin / ipamorelin / CJC-1295 stack worth it?

Documented adult GH deficiency: yes under medical supervision. Sleep + body comp + recovery in healthy adults: ipamorelin + CJC-1295 (no DAC) nightly at 250-300 mcg has community support and a tolerable side-effect profile. Sermorelin is the older, weaker option. Cycle 8-12 weeks, not continuous. Hard stop if any cancer history.

Last reviewed · Panya.health editorial

What these compounds actually do

All three are GH-secretagogues: they bind receptors on the anterior pituitary and amplify your own GH pulse rather than replacing GH directly. Sermorelin (1980s) is a 29-amino-acid GHRH analog with a short half-life. Ipamorelin (2000s) is a pentapeptide ghrelin-receptor agonist; cleaner side-effect profile than older GHRPs because it doesn't significantly elevate cortisol or prolactin. CJC-1295 is a longer-half-life GHRH analog; the version sold without DAC has a few-hour half-life, the with-DAC version (sometimes called CJC-1295 DAC) has a 6 to 8 day half-life and produces sustained GH elevation rather than pulses. Common stack: ipamorelin + CJC-1295 (no DAC) at night, 250 to 300 mcg subcutaneous each, 5 days on / 2 off, in 8 to 12 week cycles. The without-DAC version is the standard because it preserves pulsatile GH release.

When the trade is reasonable

Documented adult GH deficiency confirmed by labs (low IGF-1 + clinical picture) under endocrinologist supervision. Subjectively-reported benefits in the user community: better sleep architecture (more deep sleep), modest body composition shift over 12 weeks, improved recovery, occasionally improved injury healing. The mechanism for the sleep effect is plausible (GH pulses are coupled to slow-wave sleep). For aesthetic-medicine framing (skin elasticity, fat loss), expect modest effects at best; the dose-response data is mostly bench-science, not aesthetic-endpoint trials.

When the trade is bad

Active or recent cancer of any type. Family history of cancers driven by IGF-1 signaling (breast, prostate, colorectal). Pregnancy and breastfeeding. The IGF-1 elevation is real and dose-dependent; the cancer-pathway concern is the same one that limits exogenous HGH for non-deficient adults. Diabetes or pre-diabetes: GH elevation drives gluconeogenesis and can worsen glycemic control. Continuous use without cycling: GH-secretagogues lose effect over weeks via receptor downregulation, which is why the standard protocol cycles. Anyone using them indefinitely as 'longevity stack' is buying diminishing returns plus accumulated IGF-1 exposure.

Where Panya stands

Sermorelin is documented at panya.health/peptide/sermorelin and the ipamorelin + CJC-1295 combination at panya.health/peptide/ipamorelin-cjc-1295 with mechanism, evidence, dosing, and risk. Panya does NOT yet route to vendors for any of these compounds because non-GLP-1 vendor scoring is gated on lawyer review. Bangkok and US wellness clinics offer sermorelin / ipamorelin under prescription as part of HRT-adjacent protocols; that is a separate channel from the research-chem injectable peptides sold by Telegram resellers. The reconstitution calculator at panya.health/tools/reconstitution-calculator handles the dosing math.

Your specific match

The answer for your situation.

The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.